Today, a report focused on reimbursement pathways for psychedelic therapies in Europe was published.Authored by Magnetar Access and Blossom, the 200-odd page document aims to provide actionable insights for drug developers, payors, regulators, and other key stakeholders, and is complemented by a closer analysis of key markets such as the UK and Germany.The report is available to view via a…
